The research supported by Cure Alzheimer’s Fund has shown that a key protein turned off in cancer is excessively active in Alzheimer’s disease. This protein, called protein kinase C, is an information processor, or “signal transducer,” that regulates cellular activities. Its activity needs to be exactly balanced to maintain normal cellular function. Reduced function promotes cell survival, a hallmark of cancer. Analysis of genetic mutations identified in the Genes to Therapies program by Rudy Tanzi reveals that mutations found in some patients with Alzheimer’s disease actually enhance the function of protein kinase C. Indeed, enhanced signaling by protein kinase C generally may be associated with the pathology of Alzheimer’s disease, identifying this protein as a promising therapeutic target.